Department of Pediatrics, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
Jaeb Center for Health Research Foundation, Inc., Tampa, Florida, USA.
Diabetes Technol Ther. 2022 Aug;24(8):573-582. doi: 10.1089/dia.2021.0568. Epub 2022 Apr 28.
We recently reported that use of an "advanced" hybrid closed-loop system reduced hyperglycemia without increasing hypoglycemia compared to a first-generation system. The aim of this analysis was to evaluate whether this improved performance was specifically related to better mealtime glycemic control. We conducted a secondary analysis of postprandial glycemic control in an open-label, multinational, randomized crossover trial of 112 participants with type 1 diabetes, aged 14-29, of the Medtronic MiniMed™ 670G hybrid closed-loop system (670G) versus the Medtronic advanced hybrid closed-loop (AHCL) system, for 12 weeks each. We compared glycemic and insulin delivery metrics over a 3 h horizon across all meals to assess system performance and outcomes. Overall meal size and premeal insulin on board were similar during run-in and between 670G and AHCL arms. Compared with 670G arm, premeal, peak, and mean glucose levels were numerically lower in the AHCL arm (167 ± 23, 231 ± 23, and 177 ± 20 mg/dL vs. 175 ± 23, 235 ± 23, and 180 ± 19 mg/dL, respectively), with a trend to lower hyperglycemia level 2 in AHCL arm. Adjusting for premeal glucose level, all postmeal outcomes between 670G and AHCL were statistically similar. Prandial insulin delivery also was similar in both treatment arms (21 ± 9 vs. 23 ± 10 U), with a shift in basal/bolus ratio from 28%/71% in 670G arm to 20%/80% in AHCL arm. Reduced hyperglycemia with AHCL compared to 670G was not related to early postprandial glycemic excursions after adjusting for premeal glucose level (<3 h after meal), but likely to later (>3 h) postprandial or overnight improvements. Further refinements to mealtime bolus algorithms and strategies may more optimally control prandial glycemic excursions.
我们最近报道,与第一代系统相比,使用“先进”的混合闭环系统可以降低高血糖而不增加低血糖。本分析的目的是评估这种改进的性能是否与更好的餐时血糖控制有关。我们对 112 名年龄在 14 至 29 岁的 1 型糖尿病患者进行了一项开放标签、多国、随机交叉试验的餐后血糖控制的二次分析,这些患者使用美敦力 MiniMed™ 670G 混合闭环系统(670G)或美敦力先进混合闭环(AHCL)系统,每个系统治疗 12 周。我们比较了所有餐次在 3 小时内的血糖和胰岛素输送指标,以评估系统性能和结果。在导入期和 670G 与 AHCL 臂之间,总体餐次大小和餐前胰岛素负荷相似。与 670G 臂相比,AHCL 臂的餐前、峰值和平均血糖水平数值较低(分别为 167 ± 23、231 ± 23 和 177 ± 20mg/dL 比 175 ± 23、235 ± 23 和 180 ± 19mg/dL),且 AHCL 臂的高血糖水平 2 呈下降趋势。在校正餐前血糖水平后,670G 与 AHCL 之间所有餐后结果均具有统计学意义。在两个治疗臂中,餐前胰岛素输送也相似(21 ± 9 比 23 ± 10U),基础/大剂量比从 670G 臂的 28%/71%转变为 AHCL 臂的 20%/80%。在校正餐前血糖水平后,与 670G 相比,AHCL 降低了高血糖,但与调整后餐前血糖水平(<3 小时餐后)相关的早期餐后血糖波动无关,而可能与晚期(>3 小时)或夜间餐后血糖改善有关。进一步改进餐时大剂量算法和策略可能更优化地控制餐时血糖波动。